Evaluation of VEDAN RT-90 Resistant Cassava Starch for Glycemic Control and Prebiotic Fiber Development in a Human Trial
NCT ID: NCT07282496
Last Updated: 2025-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
115 participants
INTERVENTIONAL
2025-12-20
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Resistant Starch on Glucose and Insulin Sensitivity in Individuals With Type 2 Diabetes
NCT00691249
Effect of Tapioca-based FiberSMART® Compared to a Glucose Challenge or Water Control on Postprandial Glycemia in Healthy Subjects: An Acute Randomized Controlled Trial
NCT07075822
Effect of Resistant Starch Type 4 on Glycemia and Insulin Sensitivity in Young Adults
NCT00687960
Comparison of Different Types of Resistant Starch
NCT00930956
Safety Evaluation and Effect of Food Supplement Containing Dietary Fiber From Cassava on the Alterations of Physiological Parameters in Overweight Female Volunteers
NCT04013490
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The first phase was conducted in a randomized, cross-controlled manner. Before entering the study, participants maintained a normal diet and lifestyle for three consecutive days. Afterward, they entered the study and underwent a resistant starch assessment until the end of the study. Forty participants were randomly divided into two groups: 20 in each of the Weidan resistant starch group and the glucose powder group. Weidan resistant starch consists of tapioca resistant starch and glucose powder. Both groups consumed the sample within 5 minutes and then underwent an oral glucose tolerance test (OGTT). The participants fasted for 8-12 hours the day before the test (water was permitted). Blood samples (1 mL each) were collected at 0, 30, 60, 90, 120, and 180 minutes to monitor blood glucose levels. After the study, the two groups consumed either Weidan resistant starch or 50 g of glucose powder, each containing 50 g of total carbohydrates (57 g total product weight), dissolved in 250 mL of water, within 5 minutes, at least one week after the study. Blood glucose levels were monitored. After the study, the two groups alternated and consumed Weidan resistant starch or glucose powder again, followed by an oral glucose tolerance test and body composition measurements using the Inbody270 body composition analyzer.
The second phase of the study was conducted in a randomized, double-blind, placebo-controlled manner. Prior to entering the study, participants maintained a normal diet and lifestyle for three consecutive days. Afterward, they entered the study and underwent resistant starch assessment until completion. 75 subjects were randomly divided into three groups: the Weidan resistant starch group, the commercial resistant starch group, and the placebo control group. The ingredients of Weidan resistant starch are cassava resistant starch; the ingredients of commercial resistant starch are wheat resistant starch; and the placebo control group are natural cassava starch. The dosage is calculated based on 0.5 grams per kilogram of adult body weight (for example, a 60-kilogram adult needs to take 30 grams). The subjects were required to dissolve the test product in water and drink it on an empty stomach before their first meal each day for 12 weeks. The evaluation items at each follow-up visit included: (1) general physical examination (mental state, sleep, appetite, gastrointestinal symptoms, blood pressure, pulse and respiratory rate), (2) body measurement and body composition analysis (weight, BMI, waist circumference, hip circumference, subcutaneous fat thickness, skeletal muscle weight, body fat percentage and total water weight), (3) routine blood and biochemical examination, including red blood cell and white blood cell count, hemoglobin, hematocrit, mean corpuscular volume and platelets, renal function (urea nitrogen, creatinine, uric acid), thyroid hormone, liver function (AST, ALT, γ-GT and albumin), blood lipids (triglycerides, total cholesterol, free fatty acids, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol), electrolyte balance (sodium, potassium, chloride, phosphorus, calcium) and fasting blood glucose (blood volume was 15 mL, must fast for at least 8 hours), (4) diet and activity records (including 24-hour diet review and weekly gastrointestinal function symptom records), (5) analysis of intestinal related indicators, including short-chain fatty acids (SCFA) and intestinal flora (NGS). Samples were collected and analyzed at week 0 and week 12.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RT-90 resistant tapioca starch
Phase 1： Equivalent to 50 g total carbohydrates (57 g total product weight) of resistant starch dissolved in 250 mL of water Phase 2： The dosage is calculated at 0.5 grams per kilogram of adult body weight (e.g., a 60-kilogram adult would need to take 30 grams). Subjects should dissolve the test product in water and drink it on an empty stomach before their first meal of the day.
RT-90 resistant tapioca starch
Within 5 minutes, consume resistant starch containing 50 g of total carbohydrates (total product weight 57 g), dissolved in 250 mL of water, and perform an oral glucose tolerance test to monitor blood sugar changes. After the test, the two groups will switch and consume resistant starch or glucose powder again after at least 1 week.
control group
Phase 1：50g glucose powder, dissolved in 250 mL of water
Phase 2：The dosage is calculated at 0.5 grams per kilogram of adult body weight (e.g., a 60-kilogram adult would need to take 30 grams). Participants should dissolve the test product in water and drink it on an empty stomach before their first meal each day, continuing for 12 weeks.
control group
The subjects were asked to take a 50 g glucose powder dissolved in 250 mL of water within 5 minutes to conduct an oral glucose tolerance test to monitor blood sugar changes. After the test, the subjects were asked to empty their stomachs at least 1 week after the test and then switch to take RT-90 resistant starch or glucose powder again.
Commercially available resistant starch
The dosage is calculated at 0.5 grams per kilogram of adult body weight (e.g., a 60-kilogram adult would need to take 30 grams). Subjects should dissolve the test product in water and drink it on an empty stomach before their first meal of the day.
Commercially available resistant starch
The dosage is calculated at 0.5 grams per kilogram of adult body weight (e.g., a 60-kilogram adult would need to take 30 grams). Participants should dissolve the test product in water and drink it on an empty stomach before their first meal each day, continuing for 12 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RT-90 resistant tapioca starch
Within 5 minutes, consume resistant starch containing 50 g of total carbohydrates (total product weight 57 g), dissolved in 250 mL of water, and perform an oral glucose tolerance test to monitor blood sugar changes. After the test, the two groups will switch and consume resistant starch or glucose powder again after at least 1 week.
control group
The subjects were asked to take a 50 g glucose powder dissolved in 250 mL of water within 5 minutes to conduct an oral glucose tolerance test to monitor blood sugar changes. After the test, the subjects were asked to empty their stomachs at least 1 week after the test and then switch to take RT-90 resistant starch or glucose powder again.
Commercially available resistant starch
The dosage is calculated at 0.5 grams per kilogram of adult body weight (e.g., a 60-kilogram adult would need to take 30 grams). Participants should dissolve the test product in water and drink it on an empty stomach before their first meal each day, continuing for 12 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy subjects (BMI between 18.5-24.9 kg/m² for women and men).
* Subjects must be able to maintain a stable diet (based on the Ministry of Health and Welfare's daily dietary guidelines, with a tolerance of ± 10-15%) and physical activity (based on the World Health Organization's recommendations of 150-300 minutes of moderate-intensity exercise per week, or equivalent physical activity, with a tolerance of ± 20%) during the trial period.
* Subjects must understand the trial procedures and potential risks and benefits described in the consent form and be able to sign the consent form.
Exclusion Criteria
* Subjects with endocrine abnormalities, major organ disease, or mental illness (as determined by a physician).
* Subjects found to be intolerant to the test sample during the trial.
* Subjects who develop a disease or take medications or health supplements that could affect the results of the trial during the trial period. (e.g., hypoglycemic (lipid)-lowering medications, probiotics, high-dose dietary fiber supplements, fish oil, or supplements high in polyunsaturated fatty acids).
* Chronic gastrointestinal diseases (e.g., diverticular disease, irritable bowel syndrome, or other intestinal diseases that may cause constipation).
* Use of antibiotics within the past three months.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chung Shan Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chung Shan Medical University
Taichung, South, Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CS2-25120
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.